Castration-induced up-regulation of insulin-like growth factor binding protein-5 potentiates insulin-like growth factor-I activity and accelerates progression to androgen independence in prostate cancer models

Cancer Research

Volumn 60, Issue 11, 2000, Pages 3058-3064

  Miyake, Hideaki ^a,b   Pollak, Michael ^c   Gleave, Martin E ^a,b  

^a VANCOUVER GENERAL HOSPITAL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; MITOGEN ACTIVATED PROTEIN KINASE; SOMATOMEDIN BINDING PROTEIN 5; SOMATOMEDIN C;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER REGRESSION; CASTRATION; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CONTROLLED STUDY; GENE ACTIVITY; GENE CONTROL; GENE OVEREXPRESSION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER;

ANDROGENS; ANIMALS; BLOTTING, NORTHERN; CASTRATION; CELL CYCLE; CELL DIVISION; DISEASE PROGRESSION; DNA, ANTISENSE; DOSE-RESPONSE RELATIONSHIP, DRUG; FLOW CYTOMETRY; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 5; INSULIN-LIKE GROWTH FACTOR I; MALE; MAP KINASE SIGNALING SYSTEM; MICE; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; OLIGONUCLEOTIDES; PHENOTYPE; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION; TIME FACTORS; UP-REGULATION;

EID: 0034213320     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Denis, L., and Murphy, G. P. Overview of Phase III trials on combined androgen treatment in patients with metastatic prostate cancer. Cancer (Phila.), 72: 3888-3895, 1993.
2. Oh, W. K., and Kantoff, P. W. Management of hormone refractory prostate cancer: current standards and future prospects. J. Urol., 160: 1220-1229, 1998.
3. Jones, J. I., and Clemmons, D. R. Insulin-like growth factors and their binding proteins: biological actions. Endocr. Rev., 16: 3-34, 1995.
4. Rajaram, S., Baylink, D. J., and Mohan, S. Insulin-like growth factor-binding proteins in serum and other biological fluids: regulation and functions. Endocr. Rev., 18: 801-831, 1997.
5. Andress, D., and Birnbaum, R. Human osteoblast-derived insulin-like growth factor (IGF) binding protein-5 stimulates osteoblast mitogenesis and potentiates IGF actions. J. Biol. Chem., 267: 22467-22472, 1992.
6. Huynh, H. T., Yang, X., and Pollak, M. Estradiol and antiestrogens regulate a growth inhibitory insulin-like growth factor binding protein 3 autocrine loop in human breast cancer cells. J. Biol. Chem., 271: 1016-1021, 1996.
7. Damon, S. E., Maddison, L., Ware, J. L., and Plymate, S. R. Overexpression of an inhibitory insulin-like growth factor binding protein (IGFBP), IGFBP-4, delays onset of prostate tumor formation. Endocrinology. 139: 3456-3464, 1998.
8. Oh, Y., Muller, H. L., Lamson, G., and Rosenfeld, R. G. Insulin-like growth factor (IGF)-independent action of IGF-binding protein-3 in Hs578T human breast cancer cells. J. Biol. Chem., 268: 14964-14971, 1993.
9. Elgin, R. G., Busby, W. H., and Clemmons, D. R. An insulin-like growth factor (IGF) binding protein enhances the biological response to IGF-I. Proc. Natl. Acad. Sci. USA, 84: 3254-3258, 1987.
10. Sprenger, C. C., Damon, S. E., Hwa, V., Rosenfeld, R. G., and Plymate, S. R. Insulin-like growth factor binding protein-related protein I (IGFBP-rP1 is a potential tumor suppressor protein for prostate cancer. Cancer Res., 59: 2370-2375, 1999.
11. Boudon, C., Rodier, G., Lechevallier, E., Mottet, N., Barenton, N., and Sultan, C. Secretion of insulin-like growth factors and their binding proteins by human normal and hyperplastic prostatic cells in primary culture. J. Clin. Endocrinol. Metab., 81: 612-617, 1996.
12. Angelloz-Nicoud, P., and Binoux, M. Autocrine regulation of cell proliferation by the insulin-like growth factor (IGF) and IGF binding protein-3 protease system in a human prostate carcinoma cell line. Endocrinology, 136: 5485-5492, 1995.
13. Nickerson, T., Pollak, M., and Huynh, H. Castration-induced apoptosis in the rat ventral prostate is associated with increased expression of genes encoding insulin-like growth factor binding proteins 2, 3, 4 and 5. Endocrinology, 139: 807-810, 1998.
14. Thomas, L. N., Cohen, P., Douglas, R. C., Lazier, C., and Rittmaster, R. S. Insulin-like growth factor binding protein 5 is associated with involution of the ventral prostate in castrated and finasterido-treated rats. Prostate, 35: 273-278, 1998.
15. Nickerson, T., and Pollak, M. Bicaltamide-induced prostate regression involves increased expression of genes encoding insulin-like growth factor binding proteins. Urology, 54: 1120-1151, 1999.
16. 3 and its analogue EB1089. Int. J. Oncol., 13: 137-143, 1998.
17. Huynh, H., Seyam, R. M . and Brock, G. B. Reduction of ventral prostate weight by finasteride is associated with suppression of insulin-like growth factor 1 (IGF-I) and IGF-I receptor genes and with an increase in IGF binding protein 3. Cancer Res., 58: 215-218, 1998.
18. Figueroa, J. A., De Raad, S., Tadlock, L., Speights, V. O., and Rinehart, J. J. Differential expression of insulin-like growth factor binding proteins in high versus low Gleason score prostate cancer. J. Urol., 159: 1379-1383, 1998.
19. Miyake, H., Tolcher, A., and Gleave, M. E. Antisense Bcl-2 oligodeoxynucleotides inhibit progression to androgen-independence after castration in the Shionogi tumor model. Cancer Res., 59; 4030-4034, 1999.
20. Cleave, M. E., Hsieh, J. T., Gao, C., von Eschenbach, A. C., and Chung, L. W. K. Acceleration of human prostate carcinoma growth in vivo by factors produced by prostate and bone fibroblasts. Cancer Res., 51: 3753-3761, 1991.
21. Pollak, M., Beamer, W., and Zhang, J. Insulin-like growth factors and prostate cancer. Cancer Metastasis Rev., 17: 383-390, 1999.
22. Miyake, H., Hanada, N., Nakamura, H., Kagawa, S. Fujiwara, T., Hara, I., Eto, H., Gohji, K., Arakawa, S., Kamidono, S., and Saya, H. Overexpression of Bcl-2 in bladder cancer cells inhibits apoptosis induced by cisplatin and adenoviral-mediated p53 gene transfer. Oncogene, 16: 933-943, 1998.
23. Rennie, P. S., Bruchovsky, N., Buttyan, R., and Cheng, H. Gene expression during the early phase of regression of the androgen-dependent Shionogi mouse mammary carcinoma. Cancer Res., 48: 6309-6312, 1988.
24. Bruchovsky, N., and Rennie, P. S. Classification of dependent and autonomous variants of Shionogi mammary carcinoma based on heterogeneous patterns of androgen binding. Cell, 13: 272-280, 1978.
25. Nickerson, T., Miyake, H., Gleave, M. E., and Pollak, M. Castration-induced apoptosis of androgen-dependem Shionogi carcinoma is associated with increased expression of genes encoding insulin-like growth factor binding proteins. Cancer Res., 59: 3392-3305, 1999.
26. Pietrzkowski, Z., Mulholland, G., Gomella, L., Jameson, B. A., Wernicke, D., and Baserga, R. Inhibition of growth of prostatic cell lines by peptide analogues of insulin-like growth factors. Cancer Res., 53: 1102-1108, 1993.
27. Wolk, A., Mantzoros, C. S., Andersson, S. O., Bergstrom, R., Signorello, L. B., Lagiou, P., Adami, H. O., and Trichopoulos, D. Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study. J. Natl. Cancer Inst., 90: 911-915, 1998.
28. Conover, C. A., Bale, L. K., Clarkson, J. T., and Torring, O. Regulation of insulin-like growth factor binding protein-5 messenger ribonucleic acid expression and protein availability in rat osteoblast-like cells. Endocrinology, 132: 2525-2530, 1993.
29. Arai, T., Arai, A., Busby, W. H., Jr., and Clemmons, D. R. Glycosaminoglycans inhibit degradation of insulin-like growth factor-binding protein-5. Endocrinology, 135: 2358-2363, 1994.
30. Jones, J. I., Gockerman, A., Busby, W. H., Jr., Camacho-Hubner, C., and Clemmons, D. R. Extracellular matrix contains insulin-like growth factor binding protein-5: potentiation of the effects of IGF-I. J. Cell Biol., 121: 679-687, 1993.
31. Andress, D. L., Loop, S. M., Zapf, J., and Kiefer, M. C. Carboxytruncated insulin-like growth factor binding protein-5 stimulates mitogenesis in osteoblast-like cells. Biochem. Biophys. Res. Commun., 195: 25-30, 1993.
32. Crooke, S. T. Therapeutic applications of oligonucleotides. Annu. Rev. Pharmacol. Toxicol. 32: 329-376, 1993.
33. Saijo, Y., Perlaky, L., Wang, H., and Busch, H. Pharmacokinetics, tissue distribution, and stability of antisense oligodeoxynucleotide phosphorothioate ISIS 3466 in mice. Oncol. Res., 6: 243-249, 1994.
34. Gregory, C. W., Kim, D., Ye, P., D'Ercole, A. J., Pretlow, T. G., Mohler, J. L., and French, F. S. Androgen receptor up-regulates insulin-like growth factor binding protein-5 (IGFBP-5) expression in a human prostate cancer xenograft, Endocrinology, 140: 2372-2381, 1999.
35. Klein, K. A., Reiter, R. E., Moradi, H., Xhu, X. L. Brothman, A. R., Lamb, D. J., Marcelli, M., Belldegrum, A., Witte, O. N., and Sawyers, C. L. Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice. Nat. Med., 3: 402-408, 1997.